Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

May 18th - "Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to announce that patient enrollment has been completed in the third and final cohort of its Phase 2 open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin as a novel, non-corticosteroid, non-biologic treatment for mild-to-moderate Ulcerative Proctitis / Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD)."